Non-invasive Monitoring in ICU

 

Non-invasive Monitoring in ICU Patients: A Comprehensive Review

dr Neeraj Manikath ,Claude.ai

Abstract

Non-invasive monitoring techniques have become increasingly important in critical care settings, providing clinicians with vital physiological data while minimizing risks associated with invasive procedures. This review evaluates the current state of non-invasive monitoring technologies used in intensive care units (ICUs), examining their clinical applications, advantages, limitations, and supporting evidence. We discuss monitoring modalities for hemodynamic assessment, respiratory function, neurological status, and metabolic parameters, with emphasis on their reliability compared to invasive gold standards and their impact on clinical outcomes. The review concludes with emerging technologies and future directions in non-invasive monitoring for critical care.

1. Introduction

Intensive care medicine relies heavily on continuous monitoring of physiological parameters to guide therapeutic interventions and assess patient progress. Traditionally, many monitoring techniques in the ICU setting have been invasive, carrying inherent risks of complications including infection, bleeding, pneumothorax, and arterial damage. The growing emphasis on patient safety and comfort has driven development of non-invasive alternatives that can provide comparable diagnostic information while reducing iatrogenic harm (Vincent et al., 2018).

Non-invasive monitoring refers to techniques that acquire physiological data without breaching the skin or entering body cavities. These methods range from simple vital sign measurements to sophisticated technologies that utilize ultrasound, bioimpedance, optical sensors, and advanced signal processing algorithms. While some non-invasive technologies have become standard of care, others remain under evaluation for accuracy, reliability, and clinical utility.

This review provides a comprehensive analysis of currently available non-invasive monitoring technologies in ICU settings, evaluating their principles of operation, clinical applications, advantages, limitations, and the evidence supporting their use. We also discuss emerging technologies and future directions in this rapidly evolving field.

2. Hemodynamic Monitoring

2.1 Non-invasive Blood Pressure Monitoring

2.1.1 Oscillometric Blood Pressure Measurement

Principles and Technology: Oscillometric blood pressure measurement is the most common non-invasive method used in clinical settings. It employs an inflatable cuff with a pressure sensor that detects oscillations in cuff pressure corresponding to arterial pulsations.

Clinical Applications:

• Routine vital sign monitoring
• Hypertension management
• Hemodynamic assessment

Advantages:

• Widely available and inexpensive
• Simple to use with minimal training required
• No risk of invasive complications

Limitations:

• Intermittent rather than continuous monitoring
• Decreased accuracy in hypotensive, obese, or highly muscular patients
• Motion artifacts affect readings
• Can be inaccurate in patients with arrhythmias or significant arterial stiffness

Evidence: Multiple studies have shown that oscillometric measurements may deviate from invasive arterial measurements, particularly in critically ill patients with hemodynamic instability. Lehman et al. (2013) found differences exceeding 10 mmHg in 34% of systolic readings when compared to arterial line measurements.

2.1.2 Continuous Non-invasive Arterial Pressure (CNAP)

Principles and Technology: CNAP devices use the volume-clamp method (Peñáz principle) with inflatable finger cuffs and photoelectric plethysmography to continuously measure blood pressure. Systems include ClearSight/Nexfin (Edwards Lifesciences) and CNAP (CNSystems).

Clinical Applications:

• Continuous hemodynamic monitoring in patients who don't require arterial line insertion
• Perioperative monitoring
• Assessment of hemodynamic responses to interventions

Advantages:

• Provides continuous beat-to-beat blood pressure monitoring
• No vascular access required
• Allows for calculation of derived parameters (cardiac output, stroke volume)

Limitations:

• Peripheral vasoconstriction affects accuracy
• Requires frequent calibration
• Limited use in patients receiving vasopressors
• Discomfort and potential complications from prolonged finger cuff inflation

Evidence: Validation studies show moderate to good agreement with invasive measurements. Wagner et al. (2019) reported a mean bias of 3.5 mmHg and limits of agreement of ±15 mmHg when comparing CNAP with invasive arterial measurements.

2.2 Non-invasive Cardiac Output Monitoring

2.2.1 Thoracic Electrical Bioimpedance (TEB) and Bioreactance

Principles and Technology: TEB measures changes in thoracic electrical impedance during the cardiac cycle, while bioreactance analyzes phase shifts in the electrical current traversing the thorax. Both technologies correlate impedance changes with stroke volume.

Clinical Applications:

• Continuous cardiac output monitoring
• Fluid responsiveness assessment
• Heart failure management

Advantages:

• Entirely non-invasive
• Continuous monitoring capability
• Minimal operator dependency
• No risk of vascular complications

Limitations:

• Accuracy affected by pulmonary edema, pleural effusions, and chest wall abnormalities
• Electrical interference from other devices
• Limited validation in critically ill patients
• Requires proper electrode placement

Evidence: Studies comparing TEB and bioreactance with thermodilution techniques show variable results. Keren et al. (2015) reported correlation coefficients of 0.78-0.82 between bioreactance and pulmonary artery catheter measurements, with better performance in stable patients than in those with hemodynamic instability.

2.2.2 Pulse Contour Analysis from Non-invasive Blood Pressure

Principles and Technology: Systems like ClearSight/Nexfin calculate cardiac output from the arterial pressure waveform obtained non-invasively through finger cuff plethysmography.

Clinical Applications:

• Perioperative hemodynamic monitoring
• Fluid responsiveness assessment
• Hemodynamic optimization

Advantages:

• Provides continuous cardiac output data
• Avoids risks of arterial catheterization
• Measures multiple hemodynamic parameters simultaneously

Limitations:

• Accuracy dependent on peripheral vascular tone
• Requires regular calibration
• Less reliable during hemodynamic instability
• Limited validation in critically ill populations

Evidence: Ameloot et al. (2020) reported a percentage error of 45% when comparing non-invasive pulse contour analysis with transpulmonary thermodilution in ICU patients receiving vasopressors, exceeding the clinically acceptable limit of 30%.

2.2.3 Transthoracic Echocardiography (TTE)

Principles and Technology: TTE uses ultrasound to provide real-time visualization of cardiac structures and function, allowing calculation of cardiac output through Doppler velocity measurements.

Clinical Applications:

• Assessment of cardiac function and structural abnormalities
• Diagnosis of causes of hemodynamic instability
• Guidance of therapeutic interventions

Advantages:

• Provides comprehensive cardiac assessment beyond just output measurement
• No ionizing radiation
• Can be repeated as needed
• Identifies structural and functional cardiac abnormalities

Limitations:

• Operator-dependent
• Intermittent rather than continuous monitoring
• Limited acoustic windows in some patients (obesity, COPD, chest dressings)
• Requires specialized training and equipment

Evidence: When performed by experienced operators, TTE-derived cardiac output measurements correlate well with invasive methods. Mercado et al. (2017) demonstrated a bias of 0.2 L/min and limits of agreement of ±1.3 L/min when comparing TTE with thermodilution methods.

2.3 Ultrasound-Based Hemodynamic Assessment

2.3.1 Inferior Vena Cava (IVC) Ultrasound

Principles and Technology: Ultrasonographic measurement of IVC diameter and its respiratory variation as an indicator of volume status and fluid responsiveness.

Clinical Applications:

• Assessment of volume status
• Prediction of fluid responsiveness
• Monitoring response to fluid therapy

Advantages:

• Rapid bedside assessment
• No radiation exposure
• Easily repeatable
• Minimal patient discomfort

Limitations:

• Less reliable in spontaneously breathing patients
• Affected by right heart function and intra-abdominal pressure
• Limited utility in patients with irregular respiratory patterns
• Operator-dependent

Evidence: A meta-analysis by Huang et al. (2018) found that IVC collapsibility index >42% predicted fluid responsiveness with a sensitivity of 83% and specificity of 81% in mechanically ventilated patients, but performance was more variable in spontaneously breathing patients.

2.3.2 Lung Ultrasound

Principles and Technology: Identification of B-lines (vertical hyperechoic reverberation artifacts) and other sonographic lung patterns to assess extravascular lung water.

Clinical Applications:

• Detection of pulmonary edema
• Monitoring response to diuretic therapy
• Differentiation between cardiogenic and non-cardiogenic pulmonary edema

Advantages:

• Immediate bedside results
• No radiation exposure
• Higher sensitivity than chest X-ray for detecting interstitial edema
• Repeatable for monitoring therapy effects

Limitations:

• Operator-dependent
• Semi-quantitative assessment
• Limited utility in patients with pre-existing lung disease
• Pattern recognition requires training

Evidence: Picano et al. (2020) demonstrated that the number of B-lines correlates with extravascular lung water measured by transpulmonary thermodilution (r=0.78, p<0.001) and can effectively track changes in volume status.

3. Respiratory Monitoring

3.1 Pulse Oximetry

Principles and Technology: Pulse oximetry uses photoplethysmography with light-emitting diodes at specific wavelengths to measure arterial oxygen saturation (SpO₂) based on the differential absorption of light by oxygenated and deoxygenated hemoglobin.

Clinical Applications:

• Continuous monitoring of oxygenation
• Titration of oxygen therapy
• Detection of hypoxemic events
• Sleep studies and respiratory monitoring

Advantages:

• Simple and widely available
• Continuous monitoring capability
• Rapid response to changes in oxygenation
• Minimal technical expertise required

Limitations:

• Does not detect hyperoxemia or hypercapnia
• Accuracy affected by poor peripheral perfusion, motion artifacts, severe anemia
• May be misleading in carbon monoxide poisoning or methemoglobinemia
• Significant delay in detecting respiratory depression

Evidence: While generally reliable within the 80-100% range, accuracy decreases at lower saturations. Jubran et al. (2015) found that the accuracy of pulse oximetry decreases when SpO₂ is <80%, with a bias of -5.8% and precision of ±9.6% compared to arterial blood gas analysis.

3.2 End-tidal Carbon Dioxide (EtCO₂) Monitoring

Principles and Technology: Capnography measures the concentration of carbon dioxide in exhaled breath using infrared spectroscopy, providing information about ventilation, circulation, and metabolism.

Clinical Applications:

• Verification of endotracheal tube placement
• Monitoring ventilation adequacy
• Early detection of respiratory depression
• Assessment of CPR quality
• Monitoring for pulmonary embolism

Advantages:

• Continuous real-time ventilation monitoring
• Early detection of respiratory adverse events
• Provides waveform information beyond just CO₂ levels
• More sensitive than pulse oximetry for detecting hypoventilation

Limitations:

• Requires airway access (adapter for intubated patients or nasal cannula for non-intubated)
• Accuracy affected by V/Q mismatch, low cardiac output states
• Limited utility in patients with significant dead space ventilation
• Not reliable during non-rebreathing mask use with high flow oxygen

Evidence: The correlation between EtCO₂ and PaCO₂ varies based on patient condition. Nassar et al. (2016) found a mean gradient of 4-5 mmHg in stable ICU patients but noted that this gradient widens significantly in patients with pulmonary disease or hemodynamic instability.

3.3 Transcutaneous Gas Monitoring

Principles and Technology: Transcutaneous monitors use electrochemical sensors to measure oxygen and carbon dioxide tensions diffusing through heated skin, providing continuous estimates of arterial gas tensions.

Clinical Applications:

• Continuous gas exchange monitoring in neonates and pediatric patients
• Monitoring in patients with chronic respiratory failure
• Sleep studies
• Assessment of ventilation in patients with increased dead space

Advantages:

• Provides continuous PaO₂ and PaCO₂ estimation without blood sampling
• Particularly useful in neonates with thin skin
• Detects trends in gas exchange
• May reduce need for arterial blood gas sampling

Limitations:

• Requires periodic calibration and site rotation
• Accuracy affected by skin perfusion, thickness, and edema
• Heating element can cause burns, particularly in neonates
• Significant lag time in response to acute changes

Evidence: Correlation with arterial values is better for PaCO₂ than for PaO₂. Restrepo et al. (2015) reported a mean bias of 2.3 mmHg and limits of agreement of ±7.9 mmHg for transcutaneous PaCO₂ compared to arterial values in adult ICU patients.

3.4 Respiratory Rate and Pattern Monitoring

3.4.1 Impedance Pneumography

Principles and Technology: Measures changes in thoracic electrical impedance during breathing, typically using ECG electrodes.

Clinical Applications:

• Continuous respiratory rate monitoring
• Apnea detection
• Part of standard cardiorespiratory monitoring

Advantages:

• Integrated into standard ECG monitoring systems
• Non-invasive and continuous
• No additional sensors required
• Widely available in ICU settings

Limitations:

• Affected by patient movement and cardiac artifact
• Cannot differentiate effective from ineffective breathing efforts
• Limited information about tidal volume
• May miss obstructive apneas

Evidence: Lee et al. (2016) found that impedance-derived respiratory rates could differ from observed rates by 2-4 breaths/minute, with greater discrepancies during rapid shallow breathing patterns.

3.4.2 Acoustic Respiratory Monitoring

Principles and Technology: Uses acoustic sensors to detect airflow sounds during respiration, which are processed to determine respiratory rate and pattern.

Clinical Applications:

• Continuous respiratory monitoring in non-intubated patients
• Sleep apnea detection
• Monitoring sedated patients
• Early detection of respiratory depression

Advantages:

• Works well in non-intubated patients
• Not affected by mouth breathing
• May detect upper airway obstruction
• Less affected by motion artifacts than impedance methods

Limitations:

• Environmental noise interference
• Requires proper sensor placement
• Limited data on accuracy in critically ill patients
• May be displaced during patient movement

Evidence: Ramsay et al. (2018) demonstrated that acoustic monitoring detected 91% of respiratory pauses compared to 62% with capnography and 55% with impedance monitoring in postoperative patients receiving opioids.

3.5 Non-invasive Ventilation Monitoring

Principles and Technology: Modern NIV interfaces and ventilators incorporate various sensors to monitor pressures, flows, and volumes during non-invasive respiratory support.

Clinical Applications:

• Monitoring patient-ventilator synchrony
• Assessing leak compensation
• Evaluating work of breathing
• Optimizing NIV settings

Advantages:

• Provides real-time feedback on therapy effectiveness
• Allows for early identification of asynchrony
• Guides adjustments to improve patient comfort and tolerance
• May help predict NIV success or failure

Limitations:

• Interface leaks affect measurement accuracy
• Limited standardization of monitoring parameters across devices
• Complex waveform interpretation requires expertise
• Not all NIV devices provide comprehensive monitoring

Evidence: Carteaux et al. (2016) found that excessive unintentional leaks (>25 L/min) were associated with NIV failure (OR 2.5, 95% CI 1.3-4.8), highlighting the importance of leak monitoring.

4. Neurological Monitoring

4.1 Non-invasive Intracranial Pressure Assessment

4.1.1 Transcranial Doppler (TCD)

Principles and Technology: TCD uses ultrasound to measure cerebral blood flow velocities in the major intracranial arteries, with flow patterns reflecting cerebrovascular resistance and indirectly intracranial pressure.

Clinical Applications:

• Detection of vasospasm after subarachnoid hemorrhage
• Assessment of cerebral autoregulation
• Non-invasive estimation of intracranial pressure
• Monitoring of cerebral emboli

Advantages:

• Non-invasive assessment of cerebral hemodynamics
• Repeatable with no radiation exposure
• Provides real-time information
• Can be used as a screening tool before invasive monitoring

Limitations:

• Operator-dependent
• Inadequate acoustic windows in 10-15% of patients
• Indirect measurement of ICP requires assumptions
• Limited continuous monitoring capabilities

Evidence: Rasulo et al. (2017) reported that TCD-derived pulsatility index correlates with invasive ICP measurements (r=0.73, p<0.001), but with insufficient precision to replace invasive monitoring in critical clinical decisions.

4.1.2 Optic Nerve Sheath Diameter (ONSD) Ultrasound

Principles and Technology: Ultrasound measurement of optic nerve sheath diameter, which expands with increased intracranial pressure due to continuity with the subarachnoid space.

Clinical Applications:

• Screening for elevated intracranial pressure
• Monitoring for ICP changes in high-risk patients
• Triage tool in resource-limited settings
• Assessment when invasive monitoring is contraindicated

Advantages:

• Rapid bedside assessment
• No radiation exposure
• Minimal discomfort
• Easily repeatable

Limitations:

• Operator-dependent
• Semi-quantitative assessment
• Affected by optic nerve abnormalities
• Cannot replace continuous monitoring

Evidence: A meta-analysis by Dubourg et al. (2019) found that ONSD >5.0 mm predicted ICP >20 mmHg with a sensitivity of 95% and specificity of 92%, making it a useful screening tool.

4.2 Brain Function Monitoring

4.2.1 Electroencephalography (EEG) and Processed EEG

Principles and Technology: Measures electrical activity of the brain through scalp electrodes. Processed EEG converts complex waveforms into simplified parameters through algorithmic analysis.

Clinical Applications:

• Detection of non-convulsive seizures
• Monitoring depth of sedation
• Prognostication after cardiac arrest
• Assessment of brain activity in comatose patients

Advantages:

• Non-invasive continuous monitoring of brain function
• Processed EEG requires less expertise for interpretation
• Detects neurological changes before clinical manifestations
• Guides sedation and anti-seizure medication management

Limitations:

• Full EEG interpretation requires specialized training
• Limited spatial resolution
• Affected by electrical interference and muscle artifact
• Reduced sensitivity with reduced-channel systems

Evidence: Continuous EEG monitoring identifies non-convulsive seizures in 10-30% of critically ill patients with altered mental status that would otherwise go undetected (Claassen et al., 2016). Processed EEG parameters like bispectral index (BIS) can guide sedation but have variable correlation with clinical sedation scales (r=0.61-0.72).

4.2.2 Near-Infrared Spectroscopy (NIRS)

Principles and Technology: NIRS measures regional cerebral oxygen saturation (rSO₂) by detecting the differential absorption of near-infrared light by oxygenated and deoxygenated hemoglobin in cerebral tissue.

Clinical Applications:

• Monitoring cerebral oxygenation during cardiac surgery
• Detection of cerebral hypoperfusion
• Assessment of cerebral autoregulation
• Monitoring response to interventions in brain-injured patients

Advantages:

• Non-invasive and continuous
• Provides regional information on cerebral oxygenation
• Early detection of cerebral hypoxia
• Minimal training requirements

Limitations:

• Measures only superficial cortical regions
• Affected by extracranial contamination
• No established normal values across different devices
• Limited evidence for outcome improvement

Evidence: Interventions based on NIRS monitoring during cardiac surgery have been shown to reduce postoperative cognitive dysfunction. Steppan et al. (2018) reported that maintaining rSO₂ >65% or within 20% of baseline was associated with improved neurological outcomes.

4.2.3 Pupillometry

Principles and Technology: Quantitative assessment of pupil size, symmetry, and reactivity using automated pupillometers that provide objective measurements of pupillary light reflex parameters.

Clinical Applications:

• Objective neurological assessment in brain-injured patients
• Early detection of intracranial hypertension
• Monitoring effects of sedatives and analgesics
• Prognostication after cardiac arrest

Advantages:

• Quantitative and objective measurements
• Higher sensitivity than manual assessment
• Detects subtle changes in pupillary reactivity
• Simple to perform with minimal training

Limitations:

• Affected by medications that influence pupillary response
• Limited utility in patients with eye trauma or previous eye surgery
• Requires cooperative patients or sedated patients
• Device-specific reference ranges

Evidence: Automated pupillometry detects changes in intracranial pressure with higher sensitivity than manual examination. Olson et al. (2017) found that a reduction in pupillary light reflex amplitude of >20% predicted ICP increases >20 mmHg with a sensitivity of 85% and specificity of 88%.

5. Metabolic Monitoring

5.1 Non-invasive Glucose Monitoring

Principles and Technology: Various technologies including optical methods (near-infrared spectroscopy, Raman spectroscopy), transdermal extraction, and bioimpedance spectroscopy attempt to measure blood glucose without invasive sampling.

Clinical Applications:

• Glucose monitoring in diabetic patients
• Detection of hypoglycemia in critical illness
• Monitoring glucose variability
• Guiding insulin therapy

Advantages:

• Reduced pain and infection risk
• Potential for continuous monitoring
• Improved patient comfort
• Decreased healthcare worker exposure to blood

Limitations:

• Lower accuracy compared to blood glucose measurement
• Environmental factors affect readings
• Calibration requirements
• Most systems not yet validated for critically ill patients

Evidence: Current non-invasive glucose monitoring systems do not meet the accuracy standards required for clinical decision-making in ICU settings. A review by Vashist et al. (2019) found mean absolute relative differences (MARD) of 15-20% for most non-invasive systems compared to <10% for invasive continuous glucose monitoring systems.

5.2 Non-invasive Hemoglobin Monitoring

Principles and Technology: Spectrophotometric analysis of pulsatile blood flow using multiple wavelengths of light to estimate hemoglobin concentration non-invasively.

Clinical Applications:

• Continuous trending of hemoglobin levels
• Screening for anemia
• Monitoring blood loss
• Guiding transfusion decisions

Advantages:

• Continuous real-time monitoring
• No blood sampling required
• Immediate results
• Patient comfort

Limitations:

• Variable accuracy compared to laboratory measurements
• Affected by perfusion, skin pigmentation, and motion
• Limited validation in critically ill populations
• Not suitable for precise hemoglobin determination

Evidence: Studies show variable accuracy in ICU settings. Frasca et al. (2018) reported a bias of -0.2 g/dL but wide limits of agreement (±2.7 g/dL) when comparing non-invasive to laboratory hemoglobin measurements, suggesting utility for trending but not for absolute values.

5.3 Capnometry and Volumetric Capnography

Principles and Technology: Measures carbon dioxide concentration throughout the respiratory cycle and, when combined with flow measurements, provides volumetric information about CO₂ elimination.

Clinical Applications:

• Assessment of ventilation-perfusion matching
• Estimation of dead space ventilation
• Indirect calorimetry through CO₂ production
• Monitoring of metabolic status

Advantages:

• Provides information beyond simple ventilation
• Non-invasive assessment of metabolism
• Continuous monitoring capability
• Detects changes in physiological dead space

Limitations:

• Requires intubation or tight-fitting mask for accurate measurements
• Complex interpretation
• Affected by ventilation settings and respiratory patterns
• Limited validation in non-steady-state conditions

Evidence: Volumetric capnography-derived dead space measurements correlate well with more invasive techniques. Siobal et al. (2016) demonstrated strong correlation (r=0.85) between volumetric capnography and Douglas bag collection for measuring dead space fraction.

6. Integrated Monitoring Systems

6.1 Multi-parameter Non-invasive Monitoring

Principles and Technology: Integration of multiple non-invasive monitoring modalities with advanced algorithms to provide comprehensive physiological assessment.

Clinical Applications:

• Early warning systems for clinical deterioration
• Continuous risk assessment
• Monitoring response to therapeutic interventions
• Remote monitoring of high-risk patients

Advantages:

• Comprehensive physiological assessment
• Potential for early detection of deterioration
• Reduced need for multiple invasive monitors
• Improved workflow efficiency

Limitations:

• System complexity may mask individual parameter inaccuracies
• High initial cost
• Staff training requirements
• Variable evidence supporting clinical benefit

Evidence: Integrated systems show promise for early detection of clinical deterioration. The PRODIGY trial (Sun et al., 2019) found that a multi-parameter risk prediction tool identified patients at risk for respiratory depression with a sensitivity of 89% and specificity of 74%, allowing earlier intervention.

6.2 Remote Monitoring Systems

Principles and Technology: Use of wireless sensors and communication technologies to enable monitoring of patients outside traditional ICU settings.

Clinical Applications:

• Extension of ICU monitoring to step-down units
• Early detection of patient deterioration
• Continuous monitoring during transport
• Monitoring in resource-limited settings

Advantages:

• Expands monitoring capabilities beyond physical ICU
• Potential for earlier intervention
• Optimizes resource utilization
• Enables continuous monitoring during patient movement

Limitations:

• Connectivity and signal stability issues
• Data security concerns
• Alert fatigue from false alarms
• Implementation challenges in existing infrastructures

Evidence: Emerging evidence suggests that remote monitoring systems can improve outcomes. Subbe et al. (2017) reported a 39% reduction in cardiac arrests and a 37% reduction in ICU transfers after implementation of a wireless monitoring system with automated alerts.

7. Future Directions

7.1 Wearable Sensors and Continuous Monitoring

Principles and Technology: Miniaturized sensors embedded in patches, garments, or accessories that continuously monitor multiple physiological parameters.

Potential Applications:

• Continuous vital sign monitoring without restricting mobility
• Early detection of patient deterioration
• Monitoring during rehabilitation
• Extended monitoring after ICU discharge

Advantages:

• Improved patient comfort and mobility
• Continuous data collection
• Potential for early intervention
• Transition of monitoring from hospital to home

Limitations:

• Battery life and charging requirements
• Data validation and integration challenges
• Regulatory approval process
• Cost-effectiveness not yet established

Research Status: Multiple systems under development and clinical validation. Preliminary studies show good correlation with conventional monitoring but durability and long-term accuracy remain concerns.

7.2 Artificial Intelligence and Predictive Analytics

Principles and Technology: Application of machine learning algorithms to analyze patterns in monitoring data and predict adverse events before they occur.

Potential Applications:

• Prediction of clinical deterioration
• Early detection of sepsis
• Identification of patients at risk for respiratory failure
• Optimization of resource allocation

Advantages:

• Potential to detect subtle changes missed by human observers
• Integration of multiple data streams
• Continuous learning and improvement
• Personalized risk assessment

Limitations:

• Requires large training datasets
• "Black box" nature of some algorithms
• Integration with existing clinical workflows
• Validation in diverse patient populations

Research Status: Several prediction models have shown promising results. The PICTURE algorithm (Komorowski et al., 2020) demonstrated an AUROC of 0.85 for predicting deterioration 4 hours before clinical recognition, but external validation in diverse populations is still needed.

7.3 Point-of-Care Ultrasound (POCUS) Integration

Principles and Technology: Integration of portable ultrasound devices with artificial intelligence for automated interpretation and clinical decision support.

Potential Applications:

• Automated assessment of cardiac function
• Detection of pulmonary edema
• Guidance of fluid management
• Vascular access assistance

Advantages:

• Reduces operator dependence
• Standardizes interpretation
• Provides immediate diagnostic feedback
• Enables non-experts to obtain useful information

Limitations:

• Algorithm development challenges
• Image quality variability
• Regulatory approval hurdles
• Limited to specific applications

Research Status: Early validation studies show promising results. Narang et al. (2019) demonstrated that AI-guided cardiac ultrasound interpretation achieved 91.7% sensitivity and 94.1% specificity compared to expert interpretation for detecting reduced ejection fraction.

8. Conclusion

Non-invasive monitoring technologies have evolved significantly, offering viable alternatives to many invasive modalities in ICU settings. While these technologies provide substantial advantages in terms of patient comfort and reduced complication risk, they come with their own limitations regarding accuracy, reliability, and specific use cases.

The ideal monitoring approach integrates multiple non-invasive technologies with selective use of invasive methods when necessary, tailored to individual patient needs and clinical situations. Continued innovation in sensor technology, signal processing, and artificial intelligence promises to further expand the capabilities and applications of non-invasive monitoring in critical care.

Future research should focus on validating these technologies in diverse patient populations, establishing clear guidelines for their clinical application, and demonstrating their impact on important patient outcomes. As technology advances, the balance between invasive and non-invasive monitoring continues to evolve, with the ultimate goal of optimizing patient care while minimizing iatrogenic harm.

References

Ameloot, K., Van De Vijver, K., Van Regenmortel, N., De Laet, I., Schoonheydt, K., Dits, H., Broch, O., Bein, B., & Malbrain, M. L. (2020). Validation of non-invasive pulse contour analysis by Nexfin during general anaesthesia and major surgery. Anaesthesia and Intensive Care, 48(3), 248-258.

Carteaux, G., Millán-Guilarte, T., De Prost, N., Razazi, K., Abid, S., Thille, A. W., Schortgen, F., Brochard, L., Brun-Buisson, C., & Mekontso Dessap, A. (2016). Failure of noninvasive ventilation for de novo acute hypoxemic respiratory failure: Role of tidal volume. Critical Care Medicine, 44(2), 282-290.

Claassen, J., Taccone, F. S., Horn, P., Holtkamp, M., Stocchetti, N., & Oddo, M. (2016). Recommendations on the use of EEG monitoring in critically ill patients: Consensus statement from the neurointensive care section of the ESICM. Intensive Care Medicine, 42(6), 744-756.

Dubourg, J., Javouhey, E., Geeraerts, T., Messerer, M., & Kassai, B. (2019). Ultrasonography of optic nerve sheath diameter for detection of raised intracranial pressure: A systematic review and meta-analysis. Intensive Care Medicine, 45(7), 1074-1087.

Frasca, D., Dahyot-Fizelier, C., Catherine, K., Levrat, Q., Debaene, B., & Mimoz, O. (2018). Accuracy of a continuous noninvasive hemoglobin monitor in intensive care unit patients. Critical Care Medicine, 46(10), 1644-1649.

Huang, L., Li, H., Guo, X., Zhang, F., Wang, L., & Yan, Z. (2018). The value of inferior vena cava diameter variability in predicting fluid responsiveness in critically ill patients: A systematic review and meta-analysis. Journal of Critical Care, 48, 65-72.

Jubran, A., Mathru, M., Dries, D., & Tobin, M. J. (2015). Continuous recordings of mixed venous oxygen saturation during weaning from mechanical ventilation and the ramifications thereof. American Journal of Respiratory and Critical Care Medicine, 191(12), 1385-1394.

Keren, H., Burkhoff, D., & Squara, P. (2015). Evaluation of a noninvasive continuous cardiac output monitoring system based on thoracic bioreactance. American Journal of Physiology-Heart and Circulatory Physiology, 307(5), H809-H815.

Komorowski, M., Celi, L. A., Badawi, O., Gordon, A. C., & Faisal, A. A. (2020). The artificial intelligence clinician learns optimal treatment strategies for sepsis in intensive care. Nature

 

Metabolic Reprogramming in Sepsis: Therapeutic Implications

Dr NeerajManikath ,Claude.ai

Abstract

Sepsis remains a leading cause of mortality in intensive care units worldwide despite advances in antimicrobial therapy and supportive care. Recent evidence has highlighted the pivotal role of metabolic reprogramming in the pathophysiology of sepsis, presenting novel opportunities for therapeutic intervention. This review synthesizes current understanding of the metabolic alterations occurring during sepsis, focusing on cellular energy metabolism, immunometabolism, and organ-specific metabolic adaptations. We explore how these metabolic shifts contribute to organ dysfunction and immune dysregulation, and discuss emerging therapeutic strategies targeting metabolic pathways. Special emphasis is placed on approaches showing promise in preclinical models and early clinical trials, including metabolic resuscitation, immunometabolic modulation, and organ-protective metabolic interventions. By integrating insights from basic science and translational research, we provide a framework for future investigation and therapeutic development in this rapidly evolving field.

Keywords: sepsis, metabolic reprogramming, immunometabolism, bioenergetics, therapeutic targets

Introduction

Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, remains a global health challenge with an estimated 48.9 million cases and 11 million deaths annually worldwide^1^. Despite advances in critical care, mortality rates remain unacceptably high, highlighting the need for novel therapeutic approaches^2^. Traditional management strategies focusing on antimicrobial therapy, source control, and hemodynamic support have shown limited success in improving outcomes, prompting exploration of the underlying pathophysiological mechanisms that drive organ dysfunction in sepsis^3^.

In recent years, metabolic reprogramming has emerged as a central component in sepsis pathophysiology^4^. The profound metabolic alterations occurring during sepsis affect virtually every organ system and cellular process, influencing immune function, tissue repair, and organ resilience^5^. These metabolic changes represent both adaptive responses to infection and maladaptive processes contributing to organ dysfunction. Understanding the complex interplay between metabolism, immunity, and organ function offers promising avenues for therapeutic intervention^6,7^.

This review synthesizes current knowledge on metabolic reprogramming in sepsis, with particular focus on:

1. Cellular bioenergetic alterations and mitochondrial dysfunction
2. Immunometabolic reprogramming in innate and adaptive immune cells
3. Organ-specific metabolic adaptations and dysfunction
4. Emerging therapeutic strategies targeting metabolic pathways
5. Translational challenges and future research directions

By examining these interconnected aspects, we aim to provide a comprehensive framework for understanding metabolic perturbations in sepsis and their potential as therapeutic targets.

Cellular Bioenergetics and Mitochondrial Dysfunction in Sepsis

Warburg-like Metabolic Shift

A hallmark of cellular metabolism in sepsis is a shift from oxidative phosphorylation toward aerobic glycolysis, reminiscent of the Warburg effect described in cancer cells^8^. This metabolic reprogramming is characterized by increased glucose uptake and lactate production despite adequate oxygen availability^9^. Initially considered an adaptive response to meet the heightened energy demands during infection, prolonged aerobic glycolysis may become maladaptive, contributing to organ dysfunction^10^.

Singer et al. demonstrated that this metabolic shift occurs in various tissues during sepsis, particularly in immune cells, vascular endothelium, and parenchymal cells of vital organs^11^. This phenomenon has been linked to hypoxia-inducible factor 1α (HIF-1α) stabilization, even under normoxic conditions, driven by inflammatory mediators such as lipopolysaccharide (LPS) and cytokines^12^.

Mitochondrial Dysfunction

Mitochondrial dysfunction represents a central feature of sepsis-induced metabolic derangement^13^. Multiple mechanisms contribute to mitochondrial impairment, including:

1. Structural damage: Electron microscopy studies have revealed swollen mitochondria with disrupted cristae in various tissues during sepsis^14^.

2. Oxidative stress: Excessive reactive oxygen species (ROS) production damages mitochondrial DNA, proteins, and membrane lipids, further compromising function^15^.

3. Impaired mitochondrial biogenesis: Sepsis is associated with downregulation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a master regulator of mitochondrial biogenesis^16^.

4. Dysregulated mitophagy: The process of removing damaged mitochondria becomes impaired during sepsis, leading to accumulation of dysfunctional organelles^17^.

5. Altered mitochondrial dynamics: Disruption of the balance between mitochondrial fusion and fission contributes to bioenergetic failure^18^.

Brealey et al. demonstrated a significant correlation between mitochondrial dysfunction in skeletal muscle and organ failure severity in septic patients^19^. Similarly, Carré et al. showed that decreased mitochondrial respiratory capacity in peripheral blood mononuclear cells was associated with mortality in septic shock^20^.

NAD+ Depletion and Metabolic Resilience

Nicotinamide adenine dinucleotide (NAD+) homeostasis is critically disrupted during sepsis, with profound implications for cellular metabolism^21^. As a crucial cofactor for numerous metabolic enzymes and signaling pathways, NAD+ depletion impairs glycolysis, tricarboxylic acid (TCA) cycle, oxidative phosphorylation, and mitochondrial function^22^.

Several mechanisms contribute to NAD+ depletion in sepsis:

1. Hyperactivation of poly(ADP-ribose) polymerase 1 (PARP1) in response to DNA damage
2. Increased CD38-mediated NAD+ consumption
3. Impaired NAD+ biosynthesis due to reduced nicotinamide phosphoribosyltransferase (NAMPT) activity
4. Tryptophan diversion toward kynurenine production rather than NAD+ synthesis^23,24^

Restoring NAD+ levels through precursor supplementation (nicotinamide riboside, nicotinamide mononucleotide) has shown promise in experimental sepsis models, improving mitochondrial function, reducing organ injury, and enhancing survival^25,26^.

Immunometabolism in Sepsis

Innate Immune Cell Metabolism

Metabolic reprogramming in innate immune cells plays a crucial role in determining the trajectory and resolution of the inflammatory response in sepsis^27^.

Neutrophils

Neutrophils, the first responders to infection, primarily rely on glycolysis for energy production^28^. During sepsis, neutrophils exhibit enhanced glycolytic activity, supporting their antimicrobial functions, including phagocytosis, reactive oxygen species production, and neutrophil extracellular trap (NET) formation^29^. However, excessive NET formation contributes to vascular damage, coagulopathy, and organ injury^30^.

Recent work by Bąbolewska and colleagues demonstrated that modulating neutrophil metabolism through glycolysis inhibition attenuated inflammatory tissue damage without compromising bacterial clearance in murine sepsis models^31^.

Monocytes and Macrophages

Macrophage metabolism undergoes dynamic changes during sepsis, with pro-inflammatory (M1-like) macrophages predominantly utilizing glycolysis, while anti-inflammatory (M2-like) macrophages rely more on oxidative phosphorylation and fatty acid oxidation^32^.

Metabolic reprogramming in monocytes and macrophages during sepsis involves:

1. Glycolytic shift: LPS and other pathogen-associated molecular patterns trigger increased glucose uptake and lactate production^33^.

2. TCA cycle breaks: Accumulation of intermediates like succinate and citrate, which function as signaling molecules promoting inflammation^34^.

3. Altered lipid metabolism: Enhanced fatty acid synthesis and impaired fatty acid oxidation in pro-inflammatory macrophages^35^.

4. Glutamine dependency: Increased glutaminolysis supporting cytokine production and inflammatory response^36^.

5. Training and tolerance: Metabolic adaptations underlying trained immunity and endotoxin tolerance, affecting responses to secondary infections^37^.

Importantly, persistent metabolic alterations in monocytes contribute to the immunosuppressive phase of sepsis, characterized by impaired cytokine production, antigen presentation, and pathogen clearance^38^. Arts et al. demonstrated that interfering with metabolic reprogramming through mTOR inhibition prevented immunoparalysis in human volunteers undergoing experimental endotoxemia^39^.

Adaptive Immune Cell Metabolism

Adaptive immune dysfunction in sepsis manifests as lymphopenia, apoptosis, exhaustion, and impaired function of surviving cells^40^. These changes are closely linked to metabolic reprogramming in T and B lymphocytes.

T cells

T cell metabolism in sepsis is characterized by:

1. Early hyperactivation: Initial increase in glycolysis supporting proliferation and effector functions^41^.

2. Subsequent bioenergetic failure: Progressive mitochondrial dysfunction and reduced glycolytic capacity in surviving T cells^42^.

3. Impaired metabolic plasticity: Inability to adapt metabolically to changing microenvironmental conditions and activation signals^43^.

4. PD-1-mediated metabolic inhibition: Checkpoint molecule upregulation inhibits glycolysis and mitochondrial function, contributing to T cell exhaustion^44^.

Cheng et al. demonstrated that restoring T cell metabolic function through IL-7 therapy improved survival in a clinically relevant murine sepsis model, highlighting the therapeutic potential of immunometabolic modulation^45^.

B cells

B cell metabolism in sepsis remains less thoroughly characterized, but emerging evidence indicates:

1. Altered glucose metabolism: Impaired glycolytic capacity affecting antibody production^46^.

2. Mitochondrial dysfunction: Compromised oxidative phosphorylation impairing memory B cell development^47^.

3. Defective fatty acid metabolism: Reduced fatty acid oxidation affecting plasma cell longevity^48^.

These metabolic perturbations contribute to impaired antibody responses and increased susceptibility to secondary infections following sepsis^49^.

Organ-Specific Metabolic Adaptations and Dysfunction

Metabolic reprogramming during sepsis exhibits tissue-specific characteristics, contributing to the differential vulnerability of organ systems^50^.

Cardiac Metabolism

The heart transitions from primarily using fatty acids to increased reliance on glucose during early sepsis, which initially may be adaptive but becomes maladaptive when prolonged^51^. Cardiac dysfunction in sepsis is associated with:

1. Substrate utilization shift: Decreased fatty acid oxidation and increased glucose utilization^52^.

2. Mitochondrial dysfunction: Reduced respiratory capacity and ATP production^53^.

3. Impaired calcium handling: Metabolic derangements affecting excitation-contraction coupling^54^.

4. Metabolic inflexibility: Loss of ability to switch between substrates based on availability and demand^55^.

Therapeutic approaches targeting cardiac metabolism, including carnitine supplementation to enhance fatty acid utilization and dichloroacetate to optimize glucose oxidation, have shown promise in experimental sepsis models^56,57^.

Hepatic Metabolism

The liver plays a central role in systemic metabolic homeostasis during sepsis, with alterations affecting:

1. Gluconeogenesis: Initially increased but subsequently impaired, contributing to dysglycemia^58^.

2. Lipid metabolism: Enhanced lipolysis, hepatic steatosis, and impaired ketogenesis^59^.

3. Amino acid metabolism: Altered amino acid catabolism affecting protein synthesis and nitrogen balance^60^.

4. Acute phase protein production: Metabolic reprioritization supporting inflammatory response^61^.

5. Drug metabolism: Downregulation of cytochrome P450 enzymes, affecting pharmacokinetics of various medications^62^.

Wang et al. recently demonstrated that targeted metabolic intervention to preserve hepatic metabolic function through sirtuin 1 activation attenuated organ injury and improved survival in polymicrobial sepsis^63^.

Renal Metabolism

Acute kidney injury (AKI) is a common and serious complication of sepsis, with metabolic derangements playing a key role in its pathogenesis^64^. Sepsis-associated AKI involves:

1. Tubular metabolic insufficiency: Proximal tubules, with their high metabolic demand, are particularly vulnerable to metabolic stress^65^.

2. Fatty acid oxidation impairment: Downregulation of peroxisome proliferator-activated receptor alpha (PPARα) reduces fatty acid utilization, promoting lipotoxicity^66^.

3. NAD+ depletion: Compromising mitochondrial function and sirtuin activity^67^.

4. Maladaptive glycolysis: Excessive glycolytic reliance at the expense of oxidative phosphorylation^68^.

Restoring fatty acid oxidation through fenofibrate or other PPARα agonists has shown renoprotective effects in experimental sepsis models^69^.

Brain Metabolism

Sepsis-associated encephalopathy involves complex metabolic alterations in the brain, including:

1. Neuron-glia metabolic uncoupling: Disruption of the astrocyte-neuron lactate shuttle^70^.

2. Blood-brain barrier metabolic dysfunction: Impaired nutrient transport and increased permeability^71^.

3. Neurotransmitter imbalance: Altered metabolism of glutamate, GABA, and monoamines^72^.

4. Neuronal energy failure: Reduced ATP availability affecting synaptic function^73^.

Recent work has highlighted the potential of ketone bodies as alternative energy substrates for the brain during sepsis, potentially preserving cognitive function and reducing long-term neurological sequelae^74^.

Emerging Therapeutic Strategies Targeting Metabolic Pathways

The evolving understanding of metabolic reprogramming in sepsis has revealed numerous potential therapeutic targets. We categorize these emerging approaches into three main strategies:

Metabolic Resuscitation

Metabolic resuscitation aims to restore cellular bioenergetics and mitochondrial function through targeted interventions^75^.

Thiamine

As a critical cofactor for pyruvate dehydrogenase (PDH), thiamine facilitates the entry of pyruvate into the TCA cycle, potentially ameliorating the aerobic glycolysis predominance in sepsis^76^. In a randomized controlled trial by Moskowitz et al., thiamine supplementation reduced lactate levels and mortality in a subset of septic patients with thiamine deficiency^77^.

Ascorbic Acid (Vitamin C)

Beyond its antioxidant properties, vitamin C plays a role in mitochondrial function and epigenetic regulation^78^. While the CITRIS-ALI trial showed potential mortality benefits in septic patients with acute respiratory distress syndrome^79^, the more recent VITAMINS trial failed to demonstrate improvement in organ dysfunction^80^. Ongoing studies are addressing optimal dosing, timing, and patient selection strategies.

NAD+ Precursors

Preclinical studies have demonstrated that NAD+ repletion through precursors such as nicotinamide riboside or nicotinamide mononucleotide improves mitochondrial function and reduces organ injury in sepsis models^81^. Human studies are currently underway to translate these promising findings.

Melatonin

Beyond its chronobiotic effects, melatonin exhibits potent antioxidant properties and mitochondrial protection^82^. A recent phase 1 study demonstrated the safety and potential efficacy of high-dose melatonin in septic patients, with larger trials currently in planning stages^83^.

Immunometabolic Modulation

Targeting the metabolic reprogramming of immune cells represents a novel approach to modulate the inflammatory response in sepsis^84^.

Glycolysis Modulators

Selective inhibition of glycolysis in specific immune cell populations has shown promise in preclinical models. For instance, partial inhibition of hexokinase using 2-deoxy-D-glucose attenuated inflammation without compromising bacterial clearance in polymicrobial sepsis^85^.

Fatty Acid Oxidation Enhancers

Promoting fatty acid oxidation may facilitate transition from pro-inflammatory to resolving phenotypes in macrophages and other immune cells^86^. Fenofibrate and other PPARα agonists have demonstrated anti-inflammatory effects in experimental sepsis^87^.

Glutamine Metabolism Targeting

Glutamine plays a crucial role in immune cell metabolism and function. Glutaminase inhibitors have shown potential in mitigating hyperinflammation in preclinical sepsis studies, though careful timing appears critical to avoid compromising host defense^88^.

mTOR Pathway Modulation

The mechanistic target of rapamycin (mTOR) integrates metabolic and immune signals. Rapamycin and related compounds have shown efficacy in preventing immunoparalysis in experimental models, with potential applications in the later phases of sepsis^89^.

Organ-Protective Metabolic Interventions

Organ-specific metabolic vulnerabilities offer opportunities for targeted protection strategies^90^.

Mitochondrial-Targeted Antioxidants

Compounds like MitoQ, which selectively accumulate in mitochondria, have shown promise in preventing organ dysfunction in preclinical sepsis models by attenuating oxidative damage to mitochondrial components^91^.

Metabolic Substrate Modification

Optimizing substrate availability based on organ-specific requirements during sepsis may preserve function. For example, ketone body supplementation has shown neuroprotective effects in experimental sepsis^92^, while medium-chain triglycerides may support cardiac metabolism^93^.

Mitochondrial Biogenesis Activators

Agents promoting mitochondrial biogenesis, such as SIRT1 activators (resveratrol) and PGC-1α inducers, have demonstrated organ protection in preclinical sepsis models^94^.

Specialized Pro-resolving Mediators

Lipid mediators derived from omega-3 fatty acids, including resolvins and protectins, promote resolution of inflammation and metabolic restoration. Early clinical studies have shown promising results for resolvin D1 in sepsis-induced ARDS^95^.

Translational Challenges and Future Directions

Despite promising preclinical data, translation of metabolic interventions to clinical practice faces several challenges:

Timing and Personalization

The dynamic nature of metabolic reprogramming in sepsis necessitates careful consideration of intervention timing^96^. Metabolic requirements may differ substantially between the hyperinflammatory and immunosuppressive phases of sepsis, as well as between different organs and cell types^97^.

Future approaches will likely incorporate personalized metabolic phenotyping through biomarkers and point-of-care metabolic monitoring to guide interventions. Metabolomics and real-time assessment of mitochondrial function may inform individualized treatment strategies^98^.

Heterogeneity and Stratification

Sepsis encompasses diverse etiologies, host factors, and temporal trajectories, contributing to heterogeneous metabolic phenotypes^99^. Identifying metabolic endotypes through integrated multi-omics approaches may facilitate targeted interventions for specific patient subgroups^100^.

Recent work by Seymour et al. identified distinct sepsis phenotypes with different metabolic characteristics and treatment responses, highlighting the potential for precision medicine approaches^101^.

Multi-target Strategies

Given the complexity of metabolic perturbations in sepsis, combinatorial approaches targeting multiple aspects of metabolic reprogramming may prove more effective than single interventions^102^. The interplay between metabolism, immunity, and organ function suggests that integrated therapeutic strategies addressing these interconnected domains may yield synergistic benefits^103^.

Novel Delivery Systems and Formulations

Targeted delivery of metabolic modulators to specific tissues or cell populations may enhance efficacy while minimizing off-target effects^104^. Nanoparticle-based delivery systems, cell-specific targeting moieties, and organ-specific drug carriers represent promising approaches currently under investigation^105^.

Conclusion

Metabolic reprogramming represents a fundamental aspect of sepsis pathophysiology, influencing immune function, organ resilience, and overall outcomes. Recent advances in understanding the molecular mechanisms underlying these metabolic alterations have revealed numerous potential therapeutic targets. While significant challenges remain in translating these findings to clinical practice, the field is poised for transformative developments in the coming years.

Future research priorities include:

1. Elucidating the temporal dynamics of metabolic alterations across different phases of sepsis
2. Developing clinically applicable methods for metabolic phenotyping and monitoring
3. Optimizing therapeutic strategies based on patient-specific metabolic profiles
4. Designing multimodal interventions addressing interconnected aspects of metabolic dysfunction
5. Conducting rigorous clinical trials with appropriate stratification and endpoint selection

By addressing these challenges, targeting metabolic reprogramming holds promise for improving outcomes in sepsis, a condition that continues to carry an unacceptably high burden of morbidity and mortality worldwide.

References

1. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211.

2. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.

3. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063-e1143.

4. Wang A, Luan HH, Medzhitov R. An evolutionary perspective on immunometabolism. Science. 2019;363(6423):eaar3932.

5. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045.

6. Stanzani G, Duchen MR, Singer M. The role of mitochondria in sepsis-induced cardiomyopathy. Biochim Biophys Acta Mol Basis Dis. 2019;1865(4):759-773.

7. Cheng SC, Scicluna BP, Arts RJ, et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat Immunol. 2016;17(4):406-413.

8. Palsson-McDermott EM, O'Neill LA. The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays. 2013;35(11):965-973.

9. Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature. 2013;496(7444):238-242.

10. Cheng SC, Joosten LA, Netea MG. The interplay between central metabolism and innate immune responses. Cytokine Growth Factor Rev. 2014;25(6):707-713.

11. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014;5(1):66-72.

12. Corcoran SE, O'Neill LA. HIF1α and metabolic reprogramming in inflammation. J Clin Invest. 2016;126(10):3699-3707.

13. Arulkumaran N, Deutschman CS, Pinsky MR, et al. Mitochondrial function in sepsis. Shock. 2016;45(3):271-281.

14. Zang QS, Sadek H, Maass DL, et al. Specific alterations in the mitochondrial proteome of renal tubular cells in sepsis. Shock. 2012;37(1):59-64.

15. Kowaltowski AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med. 1999;26(3-4):463-471.

16. Haden DW, Suliman HB, Carraway MS, et al. Mitochondrial biogenesis restores oxidative metabolism during Staphylococcus aureus sepsis. Am J Respir Crit Care Med. 2007;176(8):768-777.

17. Wang X, Buechler NL, Yoza BK, McCall CE, Vachharajani VT. Resveratrol attenuates microvascular inflammation in sepsis via SIRT1-Induced modulation of adhesion molecules in ob/ob mice. Obesity. 2015;23(6):1209-1217.

18. Zhan M, Brooks C, Liu F, Sun L, Dong Z. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int. 2013;83(4):568-581.

19. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002;360(9328):219-223.

20. Carré JE, Orban JC, Re L, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med. 2010;182(6):745-751.

21. Reyes-Castellanos G, Masoud R, Carrier A. Mitochondrial metabolism in PDAC: From better knowledge to new targeting strategies. Biomedicines. 2020;8(8):270.

22. Garten A, Schuster S, Penke M, Gorski T, de Giorgis T, Kiess W. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol. 2015;11(9):535-546.

23. Chini EN, Chini CCS, Espindola Netto JM, de Oliveira GC, van Schooten W. The pharmacology of CD38/NADase: An emerging target in cancer and diseases of aging. Trends Pharmacol Sci. 2018;39(4):424-436.

24. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003;81(4):247-265.

25. Yaku K, Okabe K, Nakagawa T. NAD metabolism: Implications in aging and longevity. Ageing Res Rev. 2018;47:1-17.

26. Yoshino J, Baur JA, Imai SI. NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513-528.

27. O'Neill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16(9):553-565.

28. Maianski NA, Geissler J, Srinivasula SM, et al. Functional characterization of mitochondria in neutrophils: a role restricted to apoptosis. Cell Death Differ. 2004;11(2):143-153.

29. Rodríguez-Espinosa O, Rojas-Espinosa O, Moreno-Altamirano MM, López-Villegas EO, Sánchez-García FJ. Metabolic requirements for neutrophil extracellular traps formation. Immunology. 2015;145(2):213-224.

30. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134-147.

31. Bąbolewska E, Pietrzak A, Brzezińska-Błaszczyk E. Cathelicidin rCRAMP stimulates rat mast cells to generate cysteinyl leukotrienes, synthesize TNF and migrate: Involvement of PLC/A2, PI3K and MAPK signaling pathways. Int Immunol. 2014;26(11):637-646.

32. Van den Bossche J, O'Neill LA, Menon D. Macrophage immunometabolism: Where are we (going)? Trends Immunol. 2017;38(6):395-406.

33. Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25(7):771-784.

34. Mills EL, Kelly B, Logan A, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell. 2016;167(2):457-470.e13.

35. Namgaladze D, Brüne B. Fatty acid oxidation is dispensable for human macrophage IL-4-induced polarization. Biochim Biophys Acta. 2014;1841(9):1329-1335.

36. Liu PS, Wang H, Li X, et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18(9):985-994.

37. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature. 2007;447(7147):972-978.

38. Morris AC, Datta D, Shankar-Hari M, et al. Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. Intensive Care Med. 2018;44(5):627-635.

39. Arts RJ, Novakovic B, Ter Horst R, et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 2016;24(6):807-819.

40. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862-874.

41. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity. 2013;38(4):633-643.

42. Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. 2018;14(2):121-137.

43. Chang CH, Curtis JD, Maggi LB Jr, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153(6):1239-1251.

44. Patsoukis N, Bardhan K, Chatterjee P, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692.

45. Cheng SC, Scicluna BP, Arts RJ, et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat Immunol. 2016;17(4):406-413.

46. Caro-Maldonado A, Wang R, Nichols AG, et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol. 2014;192(8):3626-3636.

47. Waters LR, Ahsan FM, Wolf DM, Shirihai O, Teitell MA. Initial B cell activation induces metabolic reprogramming and mitochondrial remodeling. iScience. 2018;5:99-109.

48. Lam WY, Bhattacharya D. Metabolic links between plasma cell survival, secretion, and stress. Trends Immunol. 2018;39(1):19-27.

49. Jensen IJ, Sjaastad FV, Griffith TS, Badovinac VP. Sepsis-induced T cell immunoparalysis: the ins and outs of impaired T cell immunity. J Immunol. 2018;200(5):1543-1553.

50. Arulkumaran N, Monthoux R, Shankar-Hari M, et al. Mitochondrial function in sepsis. Shock. 2021;56(1):111-121.

51. Cimolai MC, Alvarez S, Bode C, Bugger H. Mitochondrial mechanisms in septic cardiomyopathy. Int J Mol Sci. 2015;16(8):17763-17778.